Clinic Roundup

Peregrine Pharmaceuticals Inc., of Tustin, Calif., completed patient enrollment in its second randomized Phase II trial for bavituximab. The company said 66 patients with previously untreated genotype-1 hepatitis C virus infection were treated with 12 weeks of ribavirin in combination with bavituximab or pegylated interferon alpha-2a.